148 related articles for article (PubMed ID: 21283016)
1. Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity.
Sajadi MM; Guan Y; DeVico AL; Seaman MS; Hossain M; Lewis GK; Redfield RR
J Acquir Immune Defic Syndr; 2011 May; 57(1):9-15. PubMed ID: 21283016
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies.
Serwanga J; Ssemwanga D; Muganga M; Nakiboneka R; Nakubulwa S; Kiwuwa-Muyingo S; Morris L; Redd AD; Quinn TC; Kaleebu P;
Vaccine; 2018 Jan; 36(4):578-586. PubMed ID: 29274699
[TBL] [Abstract][Full Text] [Related]
3. B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.
Oballah P; Flach B; Eller LA; Eller MA; Ouma B; de Souza M; Kibuuka HN; Wabwire-Mangen F; Brown BK; Michael NL; Robb ML; Montefiori D; Polonis VR
PLoS One; 2011; 6(8):e22653. PubMed ID: 21886768
[TBL] [Abstract][Full Text] [Related]
4. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study.
Gach JS; Achenbach CJ; Chromikova V; Berzins B; Lambert N; Landucci G; Forthal DN; Katlama C; Jung BH; Murphy RL
PLoS One; 2014; 9(1):e85371. PubMed ID: 24454852
[TBL] [Abstract][Full Text] [Related]
6. Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India.
Hussain SI; Panneerselvam N; Solomon S; Solomon SS; Adam K; Chandrasekaran E; Montefiori DC; Pachamuthu B
J Int Assoc Provid AIDS Care; 2017; 16(2):201-208. PubMed ID: 23422744
[TBL] [Abstract][Full Text] [Related]
7. Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.
Dieltjens T; Heyndrickx L; Willems B; Gray E; Van Nieuwenhove L; Grupping K; Vanham G; Janssens W
Retrovirology; 2009 Dec; 6():113. PubMed ID: 20003438
[TBL] [Abstract][Full Text] [Related]
8. Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India.
Vidyavijayan KK; Cheedarala N; Babu H; Precilla LK; Sathyamurthi P; Chandrasekaran P; Murugavel KG; Swaminathan S; Tripathy SP; Hanna LE
Front Immunol; 2018; 9():2841. PubMed ID: 30619250
[No Abstract] [Full Text] [Related]
9. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.
Hu X; Hong K; Zhao C; Zheng Y; Ma L; Ruan Y; Gao H; Greene K; Sarzotti-Kelsoe M; Montefiori DC; Shao Y
J Gen Virol; 2012 Oct; 93(Pt 10):2267-2278. PubMed ID: 22791603
[TBL] [Abstract][Full Text] [Related]
10. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.
Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K
J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339
[TBL] [Abstract][Full Text] [Related]
11. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
[TBL] [Abstract][Full Text] [Related]
12. Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India.
Andrabi R; Bala M; Kumar R; Wig N; Hazarika A; Luthra K
PLoS One; 2012; 7(8):e43704. PubMed ID: 22952740
[TBL] [Abstract][Full Text] [Related]
13. Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.
Andrabi R; Makhdoomi MA; Kumar R; Bala M; Parray H; Gupta A; Kotnala A; Thirumurthy V; Luthra K
J Clin Immunol; 2014 May; 34(4):504-13. PubMed ID: 24682667
[TBL] [Abstract][Full Text] [Related]
14. Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
Makhdoomi MA; Khan L; Kumar S; Aggarwal H; Singh R; Lodha R; Singla M; Das BK; Kabra SK; Luthra K
J Gen Virol; 2017 Jul; 98(7):1879-1891. PubMed ID: 28696188
[TBL] [Abstract][Full Text] [Related]
15. Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.
Sajadi MM; Lewis GK; Seaman MS; Guan Y; Redfield RR; DeVico AL
J Virol; 2012 May; 86(9):5014-25. PubMed ID: 22379105
[TBL] [Abstract][Full Text] [Related]
16. Epitope specificity of cross-clade neutralizing sera from Chinese HIV-1-positive individuals.
Song H; Chu Y; Zhang H; Wang X; Zhang T; Qiu M; Wu H; Wu Z
Scand J Immunol; 2013 Oct; 78(4):357-70. PubMed ID: 23808939
[TBL] [Abstract][Full Text] [Related]
17. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.
Malherbe DC; Pissani F; Sather DN; Guo B; Pandey S; Sutton WF; Stuart AB; Robins H; Park B; Krebs SJ; Schuman JT; Kalams S; Hessell AJ; Haigwood NL
J Virol; 2014 Nov; 88(22):12949-67. PubMed ID: 25210191
[TBL] [Abstract][Full Text] [Related]
18. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.
Medina-Ramírez M; Sánchez-Merino V; Sánchez-Palomino S; Merino-Mansilla A; Ferreira CB; Pérez I; González N; Alvarez A; Alcocer-González JM; García F; Gatell JM; Alcamí J; Yuste E
J Virol; 2011 Jun; 85(12):5804-13. PubMed ID: 21471239
[TBL] [Abstract][Full Text] [Related]
19. Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.
Cheedarla N; Precilla KL; Babu H; Vijayan KKV; Ashokkumar M; Chandrasekaran P; Kailasam N; Sundaramurthi JC; Swaminathan S; Buddolla V; Vaniambadi SK; Ramanathan VD; Hanna LE
Sci Rep; 2017 Apr; 7():46557. PubMed ID: 28436427
[TBL] [Abstract][Full Text] [Related]
20. Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.
Sanchez-Merino V; Fabra-Garcia A; Gonzalez N; Nicolas D; Merino-Mansilla A; Manzardo C; Ambrosioni J; Schultz A; Meyerhans A; Mascola JR; Gatell JM; Alcami J; Miro JM; Yuste E
J Virol; 2016 Jun; 90(11):5231-5245. PubMed ID: 26984721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
